New Medicine Development: Big Investors

Biopharma companies are crabbing up their drug research & development spending after staying stable all the way through last couple of years. According to industry sources, research & development investments will top $136 billion in 2013, up from $ 134 billion (2012); also the R&D expenditures estimated to exceed ($ 149 billion) by 2017.

Drug Development Costs: Average cost to develop a drug

• Early 2000s = $1.2 billion approx
• Late 1990s = $800 million
• Mid 1980s = $320 million
• 1970s = $140 million

New medicine development – Big investors:

• According to recent industry surveys: NovoNordisk will have the fastest growth in Research & Development spending, from $1.8 billion in 2011 to $3.1 billion in 2018, an 8 % increase in investments.
• Novartis is predicted to spend on R&D the most $10.1 billion – by 2018.
• Roche is expected to spend $8.7 billion.
• Merck & Co., is expected to spend $7.6 billion.
• GlaxoSmithKline, is expected to spend $7.2 billion
• Pfizer, is expected to spend $6.7 billion
• Sanofi, is expected to spend $6.7 billion
• Johnson & Johnson, is expected to spend $5.9 billion
• Eli Lily, is expected to spend $4.7 billion
• Bristol-Meyers Squib, is expected to spend $4.2 billion
• AstraZeneca is expected to spend $4.1 billion: according to the sources several major biopharma companies are expected to spend less on R&D over the next 6 years (including Pfizer, Merck & Co, AstraZeneca and Eli Lilly.)

Click here to Continue Reading
For more updates visit Harneedi.com